<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215913</url>
  </required_header>
  <id_info>
    <org_study_id>2019-FD52Rainy-PSC</org_study_id>
    <secondary_id>FD52Rainy</secondary_id>
    <nct_id>NCT04215913</nct_id>
  </id_info>
  <brief_title>Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)</brief_title>
  <acronym>PSC</acronym>
  <official_title>Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will analyzed proteomes of paired normal lung tissues and pulmonary
      sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole
      exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each
      comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous
      matched metastasis, as well as analyzed genomics of lung cancer characterized previously by
      The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2019</start_date>
  <completion_date type="Anticipated">December 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>10 years overall survival</measure>
    <time_frame>10 years overall survival</time_frame>
    <description>10 years overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 years disease-free survival</measure>
    <time_frame>10 years disease-free survival</time_frame>
    <description>10 years disease-free survival</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Normal lung tissue</arm_group_label>
    <description>Normal lung tissue from PSC patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSC tissues</arm_group_label>
    <description>PSC tissues from PSC patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastasis tissues</arm_group_label>
    <description>Metastasis tissues from PSC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The investigators will extract total protein, DNA and RNA from PSC patients.</intervention_name>
    <description>The investigators will extract total protein, DNA and RNA from PSC patients.</description>
    <arm_group_label>Metastasis tissues</arm_group_label>
    <arm_group_label>Normal lung tissue</arm_group_label>
    <arm_group_label>PSC tissues</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary sarcomatoid carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 70 years with histologically proven LCLC

          -  No severe major organ dysfunction

          -  World Health Organization (WHO) performance status of 0 or 1

          -  No prior cancer chemotherapy

        Exclusion Criteria:

          -  Age ≥ 70

          -  Severe major organ dysfunction

          -  WHO performance status of &gt;1

          -  Prior cancer chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Da Fu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Boland JM, Mansfield AS, Roden AC. Pulmonary sarcomatoid carcinoma-a new hope. Ann Oncol. 2017 Jul 1;28(7):1417-1418. doi: 10.1093/annonc/mdx276.</citation>
    <PMID>28637281</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Da Fu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PSC</keyword>
  <keyword>Integrative Analysis</keyword>
  <keyword>IHC</keyword>
  <keyword>WES</keyword>
  <keyword>RNA sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

